DNMT3A and myeloproliferative disorder: Notably, only 6 patients (1.7%) had mutations in DNMT3A. A history of myeloproliferative neoplasms (MPN) was noted in 37% of MF 2–3 versus 26.2% with MF 0–1 (p = 0.01).